All the DH patients studied here have prominent B‐cell responses to TG2, and the fact that DH patients have T cells reactive with deamidated gluten peptides[4e] leads us to hypothesize that DH patients, as regular CeD patients, develop an immune response to gluten involving gluten–TG2 complexes. The gene discussed is TGM2; the disease is cranioectodermal dysplasia.